Markets:

Overview

News

Currencies

International

Treasuries

Anavex Life Sciences Corp. - Common Stock (NQ:AVXL)

3.320 -0.240 (-6.74%)

Streaming Delayed Price Updated: 9:50 AM EDT, Aug 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Anavex Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Anavex Life Sciences Crashes As Last-Minute Testing Edits Cloud Drug's Impact ↗

February 01, 2022

Just two weeks ago, Anavex edited the goals of its study in Rett syndrome.

Via Investor's Business Daily

34 Stocks Moving In Tuesday's Mid-Day Session ↗

February 01, 2022

Gainers Biofrontera Inc. (NASDAQ: BFRI) shares climbed 30.7% to $4.4095 after the company provided an update on patient recruitment for the Phase III study for the treatment of...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 01, 2022

Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 25.6% to $1.42 during Tuesday's regular session. Trading volume for Windtree Therapeutics's stock is 652.4K...

Via Benzinga

Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals ↗

February 01, 2022

Anavex Life Sciences Corp (NASDAQ: AVXL) reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome.

Via Benzinga

Mid-Day Market Update: Pitney Bowes Drops After Q4 Earnings; Biofrontera Shares Climb ↗

February 01, 2022

US stocks traded mostly flat on Tuesday after recording sharp gains in the previous session. Wall Street closed the volatile January month with steep losses.

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower Following Monday's Rally; UPS Earnings Top Views ↗

February 01, 2022

US stocks started the first trading day of new month on a cautious note after recording gains on Monday. Wall Street closed the volatile January month with steep losses.

Via Benzinga

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗

February 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 14, 2022

Gainers Molecular Partners (NASDAQ:MOLN) shares moved upwards by 11.9% to $31.66 during Friday's pre-market session. The market value of their outstanding shares is at...

Via Benzinga

Anavex Life's Neurodegenerative Disease Candidate Meets Primary Endpoint In Early-Stage Study ↗

January 10, 2022

Anavex Life Sciences Corp (NASDAQ: AVXL) announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including...

Via Benzinga

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts, and COVID-19 treatment and vaccine developments dictating sentiment. Here are the key...

Via Talk Markets

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 24, 2021

Gainers iSpecimen (NASDAQ:ISPC) shares in...

Via Benzinga

The Daily Biotech Pulse: Kura's Blood Cancer Drug Study Gets Partial Clinical Hold, Takeda FDA Nod, Puma Breast Cancer Treatment Gets Patent Extension ↗

November 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Puma Biotech Announces Receipt Of Patent Extension For Breast Cancer Drug By...

Via Benzinga

Topics Intellectual Property

Earnings Scheduled For November 24, 2021 ↗

November 24, 2021

Companies Reporting Before The Bell • Centogene (NASDAQ:CNTG) is likely to report quarterly loss at $0.55 per share on revenue of $31.75 million. • Anavex Life...

Via Benzinga

Earnings Outlook For Anavex Life Sciences ↗

November 23, 2021

Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-24. Here's what investors need to know before the announcement....

Via Benzinga

The Week Ahead In Biotech (Nov. 21-Nov. 27): FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the winding down of the reporting...

Via Talk Markets

The Week Ahead In Biotech (Nov. 21-Nov. 27): Takeda, Aadi, Fennec FDA Decisions, Earnings In The Spotlight In Holiday-Shortened Week ↗

November 21, 2021

Biotech stocks showed a lack of direction in the week ending Nov. 19 before finishing modestly higher. Stocks did not have much meaningful catalysts to react to amid the...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 01, 2021

Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 55.11% to $1.11 during Monday's pre-market session. The company's market cap stands at $27.1...

Via Benzinga

Why Is Biogen Pursuing a New Direction in Alzheimer's Research? ↗

August 13, 2021

It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 ↗

September 23, 2021

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:

Via Benzinga

Anavex Life Sciences (AVXL) Q3 2021 Earnings Call Transcript ↗

August 13, 2021

AVXL earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Earnings Scheduled For August 12, 2021 ↗

August 12, 2021

Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS...

Via Benzinga

70 Biggest Movers From Yesterday ↗

July 30, 2021

Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private...

Via Benzinga

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday ↗

July 29, 2021

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 29, 2021

Gainers NanoVibronix (NASDAQ:NAOV) share...

Via Benzinga

Anavex Life's Stock Declines Despite Data Shows Alzheimer's Candidate Prevent Abeta-Induced Cognitive Decline In Animal Study ↗

July 29, 2021

Anavex Life Sciences Corp (NASDAQ: AVXL) has reported new preclinical data for its Alzheimer's candidate, ANAVEX2-73 (blarcamesine). Pre-treatment with...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 29, 2021

Gainers Cocrystal Pharma (NASDAQ:COCP) stock moved upwards by 30.9% to $1.44 during Thursday's pre-market session. The company's market cap stands at $140.3...

Via Benzinga

21 Stocks Moving in Monday's Pre-Market Session ↗

July 19, 2021

Gainers Creatd Inc (NASDAQ: CRTD) shares rose 33.9% to $4.27 in pre-market trading after dropping around 9% on Friday. Oxbridge Re Holdings Ltd (NASDAQ: OXBR) shares rose 13.2%...

Via Benzinga

Biogen Stock Drags On Alzheimer's Players As FDA Requests Review Of Aduhelm Approval ↗

July 09, 2021

Biogen stock tumbled Friday after the FDA requested an independent review of the process that led to its recent Alzheimer's approval.

Via Investor's Business Daily

Cramer Shares His Thoughts On Anavex Life Sciences, Upstart And More ↗

July 09, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said he is intrigued about Anavex Life Sciences Corp (NASDAQ: AVXL) because Biogen Inc (NASDAQ: BIIB) data doesn...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.